Case reports have detailed the loss of fusion or mutant oncoprotein expression in lineage-transformed TKI-resistant lung cancers, including EGFR-mutant and ROS1-rearranged NSCLC38,39. This evidence concerns the gene EGFR and lung carcinoma.